Longboard Pharmaceuticals, Inc. Common Stock (LBPH)

Etorro trading 970x250

About Longboard Pharmaceuticals, Inc. Common Stock

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California. Address: 6154 Nancy Ridge Drive, San Diego, CA, United States, 92121

Longboard Pharmaceuticals, Inc. Common Stock News and around…

Latest news about Longboard Pharmaceuticals, Inc. Common Stock (LBPH) common stock and company :

Longboard Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference on September 28, 2021
21 Sep, 2021 FinancialContent
What You Need To Know About Longboard Pharmaceuticals, Inc.'s (NASDAQ:LBPH) Investor Composition
10 Sep, 2021 Yahoo! Finance

If you want to know who really controls Longboard Pharmaceuticals, Inc. ( NASDAQ:LBPH ), then you'll have to look at...

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial
08 Sep, 2021 FinancialContent
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences
31 Aug, 2021 FinancialContent
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results
09 Aug, 2021 FinancialContent
40 Stocks Moving In Tuesday's Mid-Day Session
13 Jul, 2021 FinancialContent

Gainers Orbsat Corp. (NASDAQ: OSAT) shares jumped 81.7% to $12.12 after the company announced its Global Telesat Communications ...

Mid-Morning Market Update: Markets Mixed; JPMorgan Beats Q2 Views
13 Jul, 2021 FinancialContent

Following the market opening Tuesday, the Dow traded down 0.25% to 34,908.83 while the NASDAQ rose 0.15% to 14,754.89. The S&P also ...

60 Biggest Movers From Yesterday
15 Jun, 2021 FinancialContent

Gainers RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced ...

64 Biggest Movers From Friday
14 Jun, 2021 FinancialContent

Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per ...

We're Not Worried About Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn
12 Jun, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
08 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Oversold Conditions For Longboard Pharmaceuticals (LBPH)
14 May, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results
10 May, 2021 Yahoo! Finance

Commenced multiple ascending dose (MAD) portion of the Phase 1 study for LP352, a potential treatment for severe epileptic indications; topline results expected in the second half of 2021 Successfully completed an upsized initial public offering (IPO) raising approximately $84.8 million in total gross proceeds (before deducting underwriter and issuance costs)Strengthened leadership team with the addition of team members with significant life sciences experience, including Brandi Roberts as Chief Financial Officer, and leads across multiple R&D functions including clinical pharmacology, preclinical development, quality assurance, regulatory affairs, and translational scienceEnhanced the Board of Directors with the appointments of veteran biotech and pharmaceutical leaders Dr. Corinne Le Goff and Casey Lynch SAN DIEGO, May 10, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021. "Over the quarter we made significant corporate, clinical and financial progress. Our key priorities were three-fold: first, strategically assemble an outstanding leadership team and Board with a wealth of pharmaceutical experience that spans across all phases of research and clinical development and commercialization; second, advance our clinical and preclinical pipeline; and finally, secure a strong financial position by completing our IPO," stated Kevin R. Lind, Longboard’s President and Chief Executive Officer. "With the accomplishment of these important foundational steps, we believe that we are well positioned to build a world-class neuroscience drug development company and we look forward to providing updates on our progress as we execute on key milestones ahead." Program Overview: LP352, an oral, highly selective, centrally acting 5-hydroxytryptamine 2c receptor subtype (5-HT2c) superagonist, is in the MAD portion of a Phase 1 study with topline data expected in second half of this year. We plan to initiate a Phase 1b/2a clinical trial for the treatment of developmental and epileptic encephalopathies (DEEs) in the first quarter of 2022.LP143, an oral, centrally acting full agonist to the cannabinoid type 2 (CB2) receptor targeting a broad range of neurodegenerative diseases, with an initial focus in amyotrophic lateral sclerosis (ALS), is currently in Investigational New Drug (IND)-enabling studies and we anticipate submitting an IND application to the United States Food and Drug Administration (FDA) in the first quarter of 2022.LP659, an oral, selective, centrally acting sphingosine-1-phosphate (S1P) receptor modulator targeting a range of central nervous system neuroinflammatory diseases, is currently in IND-enabling studies and we anticipate submitting an IND application to the FDA in the second half of 2022. First Quarter 2021 Financial Results: Balance Sheet Highlights At March 31, 2021, Longboard’s cash and cash equivalents balance was approximately $120.9 million and approximately 16.9 million shares of Longboard voting and non-voting common stock were outstanding. Operating Results Research and development (R&D) expenses: R&D expenses were $4.4 million for the three months ended March 31, 2021 compared to $0.1 million for the period from January 3, 2020 (inception) through March 31, 2020. R&D expenses for the three months ended March 31, 2021 included $2.1 million in preclinical expenses related to advancing LP143 and LP659, $1.5 million in clinical trial expenses related to LP352 and $0.6 million in personnel-related expenses. General and administrative (G&A) expenses: G&A expenses were $1.3 million for the three months ended March 31, 2021 compared to $0.1 million for the period from January 3, 2020 through March 31, 2020. G&A expenses for the three months ended March 31, 2021 included $0.8 million of personnel-related costs and $0.4 million of professional services and legal related fees. Net loss: Net loss was $5.7 million, or $0.84 per share, for the three months ended March 31, 2021 compared to $0.2 million, or $0.05 per share, for the period from January 3, 2020 through March 31, 2020. About Longboard Pharmaceuticals Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, with negligible observed impact on 5-HT2b and 5-HT2a receptor subtypes, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases. Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. In some cases, you can identify forward-looking statements by words such as “expected,” “potential,” “plan”, “anticipate” “focused on”, and “look forward” and include, without limitation, statements about the following: Longboard’s clinical and preclinical programs, including timing of results, initiation of clinical trials, regulatory applications, progress, milestones, plans, and potential treatments; our positioning; and our focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: Risks related to Longboard’s limited operating history, financial position and need for additional capital; Longboard will need additional managerial and financial resources to advance all of its programs, and you and others may not agree with the manner Longboard allocates its resources; risks related to the development and commercialization of Longboard’s product candidates; Longboard’s product candidates are in the early phase of a lengthy research and development process, the timing, manner and outcome of research, development and regulatory review is uncertain, and Longboard’s product candidates may not advance in research or development or be approved for marketing; enrolling participants in Longboard’s ongoing and intended clinical trials is competitive and challenging; the duration and severity of the coronavirus disease (COVID-19) outbreak, including but not limited to the impact on Longboard’s clinical trials and operations, the operations of Longboard’s suppliers, partners, collaborators, and licensees, and capital markets, which in each case remains uncertain; risks related to unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Longboard or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; topline data may not accurately reflect the complete results of a particular study or trial; risks related to relying on licenses or collaborative arrangements, including lack of control and potential disputes; the entry into or modification or termination of licenses or collaborative arrangements; other risks related to Longboard’s dependence on third parties; competition; Longboard’s financial results are based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Longboard’s guidance or previously reported results; product liability or other litigation or disagreements with others; government and third-party payor actions, including relating to reimbursement and pricing; risks related to regulatory compliance; and risks relate to Longboard’s and third parties’ intellectual property rights. Additional factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law. Financial Tables Follow LONGBOARD PHARMACEUTICALS, INC.CONDENSED BALANCE SHEETS(Unaudited) (in thousands, except share and per share data) March 31, 2021 December 31, 2020 ASSETS Current assets: Cash and cash equivalents $120,851 $55,316 Prepaid expenses and other current assets 2,779 46 Total current assets 123,630 55,362 Deferred financing costs — 876 Total assets $123,630 $56,238 LIABILITIES AND EQUITY Current liabilities: Accounts payable $2,019 $1,213 Accrued research and development expenses 1,051 916 Accrued other expenses 699 845 Accrued compensation and related expenses 275 161 Total current liabilities 4,044 3,135 Commitments and contingencies Convertible preferred stock: Series A convertible preferred stock $0.0001 par value; authorized shares - none and 5,600,000 at March 31, 2021 and December 31, 2020, respectively; issued and outstanding shares - none and 5,600,000 at March 31, 2021 and December 31, 2020, respectively; aggregate liquidation preference – none and $56,000 at March 31, 2021 and December 31, 2020, respectively — 55,795 Stockholders’ equity (deficit): Preferred stock, $0.0001 par value; authorized shares - 10,000,000 and none at March 31, 2021 and December 31, 2020, respectively; issued and outstanding shares - none at March 31, 2021 and December 31, 2020 — — Voting common stock, $0.0001 par value; authorized shares - 300,000,000 and 10,500,000 at March 31, 2021 and December 31, 2020, respectively; issued and outstanding shares - 12,939,140 and 3,840,540 at March 31, 2021 and December 31, 2020, respectively, both excluding 348,450 shares subject to repurchase 1 — Non-voting common stock, $0.0001 par value; authorized shares - 10,000,000 and none at March 31, 2021 and December 31, 2020, respectively; issued and outstanding shares - 3,629,400 and none at March 31, 2021 and December 31, 2020, respectively — — Additional paid-in capital 139,684 11,708 Accumulated deficit (20,099) (14,400)Total stockholders’ equity (deficit) 119,586 (2,692) Total liabilities, convertible preferred stock and stockholders’ equity (deficit) $123,630 $56,238 LONGBOARD PHARMACEUTICALS, INC.CONDENSED STATEMENTS OF OPERATIONS(Unaudited) (in thousands, except share and per share data) Three Months Ended March 31, 2021 Period from January 3, 2020 (Inception) throughMarch 31, 2020 Operating expenses: Research and development 4,398 59 General and administrative 1,305 115 Total operating expenses 5,703 174 Loss from operations (5,703) (174)Interest income 4 — Net loss and comprehensive loss $(5,699) $(174) Net loss per share, basic and diluted $(0.84) $(0.05) Weighted-average shares outstanding, basic and diluted 6,810,407 3,711,084 CONTACT: Corporate Contact: Megan E. Knight Head of Investor Relations mknight@longboardpharma.com IR@longboardpharma.com 619.592.9775

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
06 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
05 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
04 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
28 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
23 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
22 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

30 Stocks Moving In Wednesday's Mid-Day Session
14 Apr, 2021 FinancialContent

Gainers Discovery, Inc. (NASDAQ: DISCB) shares climbed 37.3% to $102.99. Grupo Televisa, S.A.B. (NYSE: TV) shares climbed 22.4% ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
14 Apr, 2021 FinancialContent

Gainers Akumin (NASDAQ:AKU) shares increased by 13.54% to $3.52 during Wednesday's pre-market session. The market ...

The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
14 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Wednesday Morning
14 Apr, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're at the midpoint of the week and InvestorPlace.com is taking a look at the biggest pre-market movers for investors to keep an eye on. The post Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Wednesday Morning appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now

22 Stocks Moving in Wednesday's Pre-Market Session
14 Apr, 2021 FinancialContent

Gainers Galectin Therapeutics Inc. (NASDAQ: GALT) rose 37.6% to $2.98 in pre-market trading after the company said a paper ...

The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
13 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
08 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2021
07 Apr, 2021 FinancialContent

Upgrades According to Janney Capital, the prior rating for Texas Capital Bancshares Inc (NASDAQ:TCBI) was changed from ...

The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award
07 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2021
06 Apr, 2021 FinancialContent

Upgrades Craig-Hallum upgraded the previous rating for BBQ Holdings Inc (NASDAQ:BBQ) from Hold to Buy. BBQ Hldgs earned ...

The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight
03 Apr, 2021 FinancialContent

Biotech stocks ended the holiday-shortened week ended April 1 in the green, catalyzed by the broader market rebound and a slew of ...

Longboard Pharmaceuticals, Inc. Common Stock (LBPH) is a NASDAQ Common Stock listed in , ,

970x250